Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib with Ibrutinib or Acalabrutinib in R/R CLL
NCT04685915Phase 2Withdrawn
- Start
- Feb 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of copanlisib in chronic lymphocytic leukemia (CLL). Planned start Feb 2021; status: withdrawn.
02
Drugs
copanlisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04685915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04685915.